Long-term Effects and Prognostic Factors of Accelerated Cross-Linking with Retention Ring-assisted Riboflavin Application on Keratoconus Progression
Korean Journal of Ophthalmology · 2025
DOI: 10.3341/kjo.2025.0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, 2025. Verfasst von Seonghwan Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Riboflavin, Keratoconus, Cross-Linking Reagents, Photochemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the long-term efficacy, safety, and prognostic factors of pulsed-light accelerated corneal collagen cross-linking (A-CXL) with continuous riboflavin application to halt keratoconus progressionMethods: A-CXL with retention ring-assisted continuous riboflavin application for either 10 or 5 minutes was performed in 37 eyes of 33 patients with progressive keratoconus between 2016 and 2020. Successful halting rates and prognostic factors of time-dependent changes in keratometric values, visual acuity, refractive errors, topographic indices, central corneal thickness, thinnest corneal thickness, irregularity at 3- and 5-mm zone, and endothelial cell density were evaluated.
Results
Survival analysis showed successful halting rates of 71% and 89% in A-CXL with 5- and 10-minute–applied riboflavin, respectively. Best-corrected visual acuity significantly improved after A-CXL in both groups. Maximum keratometry decreased significantly from 52.52 to 50.39 diopters (p < 0.001) in the 10-minute group, while there was no significant decrease in the 5-minute group (52.77–51.80 diopters, p = 0.146). irregularity in 3- and 5-mm zone decreased significantly in the 10-minute group, while there was no difference in 5-minute group. Central corneal thickness and thinnest corneal thickness did not differ, and endothelial cell density changes were within acceptable ranges in both groups before and after the surgery. Among keratometric values, keratometric astigmatism was significantly related to posttreatment corneal flattening effect in multivariate regression analysis.
Conclusions
A-CXL with continuous riboflavin application for 10 minutes is an effective and safe treatment for preventing keratoconus progression. In addition, higher corneal astigmatism showed greater posttreatment corneal flattening effect in successfully treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
- Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
- Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
- Transplantation Research Institute, Seoul National University Medical Research Center, Seoul, Korea.
Zitieren
APA
Kim, S., Choi, W. J., Yoon, C. H., & Kim, M. K. (2025). Long-term Effects and Prognostic Factors of Accelerated Cross-Linking with Retention Ring-assisted Riboflavin Application on Keratoconus Progression. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2025.0001
Vancouver
Kim S, Choi WJ, Yoon CH, Kim MK. Long-term Effects and Prognostic Factors of Accelerated Cross-Linking with Retention Ring-assisted Riboflavin Application on Keratoconus Progression. Korean Journal of Ophthalmology. 2025. doi:10.3341/kjo.2025.0001
BibTeX
@article{Kim2025,
author = {Kim, Seonghwan and Choi, Won Jong and Yoon, Chang Ho and Kim, Mee Kum},
title = {Long-term Effects and Prognostic Factors of Accelerated Cross-Linking with Retention Ring-assisted Riboflavin Application on Keratoconus Progression},
journal = {Korean Journal of Ophthalmology},
year = {2025},
doi = {10.3341/kjo.2025.0001}
}
EUVIMED